2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2011
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal Of Medicine 2011, 365: 1492-1501. PMID: 22010915, PMCID: PMC3233684, DOI: 10.1056/nejmoa1014181.Peer-Reviewed Original ResearchConceptsImmune reconstitution inflammatory syndromeT-cell countsEarly ART groupLater-ART groupInitiation of ARTAntiretroviral therapyTuberculosis treatmentIncidence rateCubic millimeterAdverse eventsRisk of IRISHuman immunodeficiency virus (HIV) infectionReconstitution inflammatory syndromeMedian viral loadImmunodeficiency virus infectionAIDS-free survivalRisk of AIDSHigher CD4Median CD4Inflammatory syndromeAmbulatory patientsImmunodeficiency syndromeViral loadContinuation phaseAntiretroviral drugs
2010
Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts
Shenoi SV, Escombe AR, Friedland G. Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts. Clinical Infectious Diseases 2010, 50: s231-s237. PMID: 20397953, PMCID: PMC3029014, DOI: 10.1086/651496.Peer-Reviewed Original ResearchConceptsInfection control strategiesResource-limited settingsHIV infectionInfection controlActive antiretroviral therapy rolloutHuman immunodeficiency virus (HIV) infectionAntiretroviral therapy rolloutTransmission of drugDrug-resistant TBImmunodeficiency virus infectionDrug-resistant tuberculosisHealth care workersAirborne infection controlNosocomial transmissionTuberculosis careVirus infectionCare workersInfectionCurrent outbreakHigh rateTBPotential benefitsMorbidityHIVTuberculosis
2008
Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa
Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW, Collaboration O. Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa. The Journal Of Infectious Diseases 2008, 198: 1582-1589. PMID: 18847372, DOI: 10.1086/592991.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisXDR tuberculosisExogenous reinfectionHuman immunodeficiency virus (HIV) infectionEffective infection control strategiesInitial isolatesCause of MDRTB treatment programsTransmission of MDRCulture-positive tuberculosisHIV infection statusImmunodeficiency virus infectionInfection control strategiesDevelopment of MDRResistant tuberculosisMultidrug-ResistantHigh prevalenceVirus infectionPatientsReinfectionRural South AfricaTreatment programTuberculosisInfection statusTugela Ferry
2007
Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa
Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa. The Journal Of Infectious Diseases 2007, 196: s482-s490. PMID: 18181698, DOI: 10.1086/521121.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisMDR-TBHIV epidemicXDR-TBDrug-resistant (XDR) TBMultidrug-resistant (MDR) TBMDR-TB treatment programmeTB treatment success rateHuman immunodeficiency virus (HIV) infectionAntiretroviral therapy rolloutXDR-TB epidemicImmunodeficiency virus infectionTreatment success rateDrug resistance surveillanceDrug resistance testingPublic health challengeAirborne infection controlPublic health infrastructureHIV programsMultidrug-ResistantHigh prevalenceVirus infectionInfection controlTreatment programTuberculosis
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries
Friedland G, Karim S, Karim Q, Lalloo U, Jack C, Gandhi N, Sadr W. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases 2004, 38: s421-s428. PMID: 15156433, DOI: 10.1086/421407.Peer-Reviewed Original ResearchConceptsHIV infectionAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionTherapy programHIV/AIDS careObserved therapy programActive antiretroviral therapyImmunodeficiency virus infectionImmune deficiency syndromeBurden of diseaseResource-limited countriesResource limited countriesHIV/AIDSHIV diseaseTuberculosis careDisease burdenDeficiency syndromeAIDS careVirus infectionTuberculosisInfectionMajor causeDiseaseTherapyInadequate access
2003
Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians
Schreibman T, Friedland G. Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians. Clinical Infectious Diseases 2003, 36: 1171-1176. PMID: 12715313, DOI: 10.1086/374359.Peer-Reviewed Original ResearchConceptsHIV infectionClinical practiceHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionNew HIV infectionsClinical care sitesPrevention-related activitiesClinical care settingsIntegration of preventionEffective prevention programsPublic health modelFuture prevention activitiesSpecific prevention effortsHIV diseaseVirus infectionCare settingsCare sitesBehavioral counselingClinical careMedical interventionsPrevention programsInfectionPrevention effortsHealth modelPrevention activities
1996
Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection
Frankel R, Virata M, Hardalo C, Altice F, Friedland G. Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1996, 23: 577-584. PMID: 8879783, DOI: 10.1093/clinids/23.3.577.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal diseaseClinical featuresPenicillin-resistant pneumococcal infectionsHuman immunodeficiency virus (HIV) diseaseHuman immunodeficiency virus (HIV) infectionCommon capsular typesSource of bacteremiaImmunodeficiency virus infectionOverall mortality rateAntibiotic susceptibility patternPolyvalent pneumococcal vaccineType 9VCommon risk factorsPenicillin-resistant isolatesAntimicrobial resistance patternsPneumococcal infectionPneumococcal vaccineHIV infectionHIV serostatusHIV statusRecurrence rateInvasive diseaseRisk factorsSusceptibility patternsA prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY.
Gourevitch M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, Friedland G, Klein R. A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. American Journal Of Public Health 1996, 86: 1112-5. PMID: 8712270, PMCID: PMC1380622, DOI: 10.2105/ajph.86.8_pt_1.1112.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seronegative patientsHIV-seropositive patientsDrug usersHIV infectionEarly syphilisProspective studyHuman immunodeficiency virus (HIV) infectionHigh-risk sexual activityPercent of HIVImmunodeficiency virus infectionMethadone maintenance treatmentDrug-using womenMultiple sex partnersDiagnosis of syphilisEarly syphilis incidenceFemale drug usersHIV seroconversionHIV seroconvertersMaintenance treatmentIncidence rateIndependent riskVirus infectionSyphilis incidencePatients
1995
Injection Drug Use and Human Immunodeficiency Virus Infection
Alcabes P, Friedland G. Injection Drug Use and Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1995, 20: 1467-1479. PMID: 7548494, DOI: 10.1093/clinids/20.6.1467.Peer-Reviewed Original ResearchConceptsSurveillance case definitionHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDrug usersCase definitionInjection drugsVirus infectionPrevention (CDC) surveillance case definitionDiagnosis of AIDSInjection drug useInjection drug usersHigh mortality rateHIV diseaseHIV infectionDrug injectorsMortality rateDrug useNew casesNatural historyDisease controlAIDSDiagnostic facilitiesAIDS epidemicInitial epidemicLack of advocates
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groups
1993
A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients
Silberstein C, O'Dowd M, Chartock P, Schoenbaum E, Friedland G, Hartel D, McKegney F. A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients. General Hospital Psychiatry 1993, 15: 351-359. PMID: 8112557, DOI: 10.1016/0163-8343(93)90001-5.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCentral nervous system impairmentHIV antibody testingImmunodeficiency virus infectionMethadone-maintained patientsSymptoms/signsNervous system impairmentMethadone maintenance clinicsNeuropsychological Screening BatteryTrail Making B testSubtle cognitive deficitsHIV infectionAntibody testingPhysical examMaintenance clinicsVirus infectionBaseline testingNeuropsychological functionCognitive deficitsNP assessmentFinger tappingSystem impairmentScreening batteryLongitudinal studyPatientsEffects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users.
Gourevitch M, Selwyn P, Davenny K, Buono D, Schoenbaum E, Klein R, Friedland G. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Annals Of Internal Medicine 1993, 118: 350-5. PMID: 8094280, DOI: 10.7326/0003-4819-118-5-199303010-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersTreatment of syphilisStages of syphilisSerologic manifestationsDrug usersNontreponemal titersHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programHIV serologic statusHIV-seronegative patientsHIV-seropositive patientsImmunodeficiency virus infectionHIV seropositive casesMaintenance treatment programFulminant manifestationCD4 countCohort studyHIV-seropositiveClinical courseStandard dosesEarly syphilisClinical manifestationsSerologic statusSerologic tests
1992
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein R, Davenny K, Friedland G. Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 327: 1697-1703. PMID: 1359411, DOI: 10.1056/nejm199212103272401.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCandidiasis, OralCD4-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMaleMultivariate AnalysisNew York CityProportional Hazards ModelsProspective StudiesRacial GroupsSubstance Abuse, IntravenousZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSInjection drug usersBacterial infectionsDisease progressionOral candidiasisVirus infectionSite primary medical careMultiple constitutional symptomsPyogenic bacterial infectionsHIV-seropositive patientsPercentage of CD4Cohort of patientsDiagnosis of AIDSMethadone treatment programsProportional hazards regressionProduct-limit survival analysisIncidence of AIDSPrimary medical careRate of progressionRisk of AIDSSeronegative patientsConstitutional symptomsSeropositive patients
1991
Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection?
Khabbaz R, Hartel D, Lairmore M, Horsburgh C, Schoenbaum E, Roberts B, Hartley T, Friedland G. Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection? The Journal Of Infectious Diseases 1991, 163: 252-256. PMID: 1988509, DOI: 10.1093/infdis/163.2.252.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman T-lymphotropic virus type II (HTLV-II) infectionHTLV-II infectionType II infectionPolymerase chain reactionRisk factorsHTLV-IIDrug usersHuman immunodeficiency virus (HIV) infectionHIV infection statusImmunodeficiency virus infectionIntravenous drug useMethadone maintenance programTransfusion historyNeedle sharingVirus infectionSerologic resultsSex partnersDrug useShooting galleriesEndemic infectionInfectionOlder ageInfection statusOld infectionDemographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York.
Schrager L, Friedland G, Feiner C, Kahl P. Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York. Public Health Reports 1991, 106: 78-84. PMID: 1899944, PMCID: PMC1580205.Peer-Reviewed Original ResearchConceptsDrug usersDemographic characteristicsDrug useHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersMontefiore Medical CenterMethadone maintenance programSharing of needlesInjection of drugsSexual behaviorDrug use behaviorsDrug use practicesHIV infectionImmunodeficiency syndromeVirus infectionMedical CenterEpidemiologic informationShooting galleriesCocaine useAIDSInjection episodesSexual practicesEarly ageInfection
1990
Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus.
Feingold AR, Vermund SH, Burk RD, Kelley KF, Schrager LK, Schreiber K, Munk G, Friedland GH, Klein RS. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 896-903. PMID: 2166784.Peer-Reviewed Original ResearchConceptsSquamous intraepithelial lesionsHIV-positive womenCervical cytologic abnormalitiesCytologic abnormalitiesCervical cytologyAsymptomatic HIV-positive womenHuman immunodeficiency virus (HIV) infectionHIV-negative womenHuman papillomavirus infectionImmunodeficiency virus infectionSymptomatic HIV infectionIntravenous drug useHuman immunodeficiency virusIntravenous drug usersFemale genital tractWestern blot confirmationCervicovaginal lavageHPV determinationSeronegative womenHPV infectionPapillomavirus infectionCytological lesionsHIV infectionIntraepithelial lesionsImmunodeficiency virus
1989
Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users
Schoenbaum E, Hartel D, Selwyn P, Klein R, Davenny K, Rogers M, Feiner C, Friedland G. Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users. New England Journal Of Medicine 1989, 321: 874-879. PMID: 2770823, DOI: 10.1056/nejm198909283211306.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersPercentage of injectionsRisk factorsHIV antibodiesDrug usersIntravenous drugsVirus infectionSex partnersSeroprevalence of HIVIndependent risk factorOnly risk factorMethadone treatment programsNumber of injectionsNon-Hispanic whitesHeterosexual sex partnersHIV infectionLast injectionUsed needlesHigh seroprevalenceDrug useShooting galleriesHIVInfectionProspective Study of Human Immunodeficiency Virus Infection and Pregnancy Outcomes in Intravenous Drug Users
Selwyn P, Schoenbaum E, Davenny K, Robertson V, Feingold A, Shulman J, Mayers M, Klein R, Friedland G, Rogers M. Prospective Study of Human Immunodeficiency Virus Infection and Pregnancy Outcomes in Intravenous Drug Users. JAMA 1989, 261: 1289-1294. PMID: 2915455, DOI: 10.1001/jama.1989.03420090053030.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPregnancy outcomesDrug usersVirus infectionFemale intravenous drug usersHIV disease statusSeropositive pregnant womenAdverse pregnancy outcomesAsymptomatic HIV infectionNeonatal complicationsEctopic pregnancyPreterm deliveryHIV antibodiesBreech presentationHIV infectionSymptomatic diseaseBacterial pneumoniaHIV statusPregnant womenProspective studyWeight birthsAdditional womenMethadone programs